唑来膦酸注射液联合钙尔奇D治疗糖尿病骨质疏松的临床效果及安全性(1)
[摘要]目的 探討唑来膦酸注射液联合钙尔奇D治疗糖尿病骨质疏松的临床效果及安全性。方法 选择2012年4月～2016年4月我院收治的77例糖尿病骨质疏松症患者为研究对象，按随机数字表法分组，观察组39例，对照组38例，对照组采用常规降糖治疗联合钙尔奇D治疗，观察组在对照组基础上加用唑来膦酸注射液，对两组患者治疗后骨密度变化、骨代谢情况、不良反应等进行观察。结果 治疗前，两组患者股骨颈、腰椎骨、Ward′s三角区的骨密度无明显差异(P>0.05)，治疗后，两组患者骨密度水平均有改善，观察组治疗后骨密度明显较对照组高，差异有统计学意义(P<0.05)；治疗前，两组患者ALP、Ca、P、HCT、BGP等骨代谢指标无明显差异(P>0.05)，治疗后，对照组ALP低于治疗前，其余指标无明显差异(P>0.05)，观察组治疗后各项指标均有变化，与对照组对比差异有统计学意义(P<0.05)。两组患者均无严重不良反应，观察组有2例患者出现恶心、骨痛、低热等症状，经对症处理后消失。结论 唑来膦酸联合钙尔奇D可提高糖尿病骨质疏松患者骨密度，改善骨代谢状态，且安全性高，值得临床推广。
[关键词]钙尔奇D；唑来膦酸；糖尿病骨质疏松；骨密度
[中图分类号] R587.2 [文献标识码] A [文章编号] 1674-4721(2017)06(a)-0024-03
[Abstract]Objective To probe into the clinical effects and safety of Zoledronic Acid Injection combined with Caltrate D in treatment of diabetic osteoporosis.Methods 77 cases of patients with diabetic osteoporosis and who accepted treatments in our hospital from April 2012 to April 2016 were selected as the research object，and were grouped by the random number table method，the observation group of 39 cases and the control group of 38 cases.The control group were used the conventional hypoglycemic therapy combined with Caltrate D treatment，while the observation group was added with Zoledronic Acid Injection on the basis of the control group.Then，the changes of bone mineral density，bone metabolism and adverse reactions after treatment of two groups of patients were observed.Results Before treatment，there was no significant difference in bone mineral density of the femoral neck，lumbar spine and Ward′s triangle between the two groups(P>0.05)，after the treatment，the bone mineral density levels of two groups of patients were improved，and the bone mineral density after treatment in the observation group was significantly higher than that of the control group，the difference was statistically significant(P<0.05).Before the treatment，there was no significant difference in the ALP，Ca，P，HCT，BGP and other bone metabolic markers between two groups of patients(P>0.05)，after the treatment，the ALP in the control group was lower than that before treatment， and there was no significant difference between the other indexes(P>0.05)，and the changes of the indexes in the observation group were statistically significant compared with the control group(P<0.05).There was no serious adverse reactions of two groups of patients，the observation group had 2 cases of nausea， bone pain， fever and other symptoms， disappeared after symptomatic treatment.Conclusion The Zoledronic acid combined with Caltrate D which can improve bone mineral density in patients with diabetic osteoporosis，improve bone metabolism，and safety is high，thus it is worthy to be promoted., 百拇医药(黄冰)
[关键词]钙尔奇D；唑来膦酸；糖尿病骨质疏松；骨密度
[中图分类号] R587.2 [文献标识码] A [文章编号] 1674-4721(2017)06(a)-0024-03
[Abstract]Objective To probe into the clinical effects and safety of Zoledronic Acid Injection combined with Caltrate D in treatment of diabetic osteoporosis.Methods 77 cases of patients with diabetic osteoporosis and who accepted treatments in our hospital from April 2012 to April 2016 were selected as the research object，and were grouped by the random number table method，the observation group of 39 cases and the control group of 38 cases.The control group were used the conventional hypoglycemic therapy combined with Caltrate D treatment，while the observation group was added with Zoledronic Acid Injection on the basis of the control group.Then，the changes of bone mineral density，bone metabolism and adverse reactions after treatment of two groups of patients were observed.Results Before treatment，there was no significant difference in bone mineral density of the femoral neck，lumbar spine and Ward′s triangle between the two groups(P>0.05)，after the treatment，the bone mineral density levels of two groups of patients were improved，and the bone mineral density after treatment in the observation group was significantly higher than that of the control group，the difference was statistically significant(P<0.05).Before the treatment，there was no significant difference in the ALP，Ca，P，HCT，BGP and other bone metabolic markers between two groups of patients(P>0.05)，after the treatment，the ALP in the control group was lower than that before treatment， and there was no significant difference between the other indexes(P>0.05)，and the changes of the indexes in the observation group were statistically significant compared with the control group(P<0.05).There was no serious adverse reactions of two groups of patients，the observation group had 2 cases of nausea， bone pain， fever and other symptoms， disappeared after symptomatic treatment.Conclusion The Zoledronic acid combined with Caltrate D which can improve bone mineral density in patients with diabetic osteoporosis，improve bone metabolism，and safety is high，thus it is worthy to be promoted., 百拇医药(黄冰)